Sovaldi Sells Big in First Year

Share on Facebook
According to a Wall Street Journal report, Sovaldi, a newly approved drug to treat Hepatitis C, could see between $5 billion and $9 billion in sales during its first year on the market, one of the largest sales for a new drug's first year.

Read the full report on Becker's Hospital Review.

© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New from Becker's ASC Review

Olympus Launches Two New Endoscopes for Bronchoscopy

Read Now